Table 1 Clinical and demographic characteristics in both groups
RA group (n = 100) | Control group (n = 51) | P value | |
|---|---|---|---|
Age in years (mean ± SD) | 54.65 ± 11.35 | 53 ± 10.6 | 0.3431 |
Females (%) | 92 (92%) | 45 (88.2%) | 0.5272 |
Males (%) | 8 (8%) | 6 (11.76%) | |
BMI (kg/m2) (mean ± SD) | 29.51 ± 6.81 | 29.518 ± 6.890 | 0.1261 |
Postmenopausal women (%) | 44 (44%) | 22 (43.1%) | 0.9192 |
Premenopausal women (%) | 48 (48%) | 23 (45.09%) | |
Premenopausal normal BMD (%) | 26(54.1%) | 23 (100%) | 0.0322 |
Premenopausal osteoporosis (%) | 22 (45.8%) | 0 (0%) | |
Postmenopausal normal BMD (%) | 12 (27.27%) | 7 (31.8%) | 0.0452 |
Postmenopausal osteopenia (%) | 14 (31.8%) | 10 (45.45%) | |
Postmenopausal osteoporosis (%) | 18 (40.9%) | 5 (22.7%) | |
Men (< 50 years) normal BMD | 5 (62.5%) | 6 (100%) | 0.0912 |
Men (< 50 years) osteoporosis | 3 (37.5%) | 0 | |
Postmenopausal women menopausal years (mean ± SD) | 5.818 ± 3.500 | 5.5 ± 2.84 | 0.9431 |
Disease duration (mean ± SD) | 6.12 ± 5.02 | ||
RA patients on MTX (%) | 47 (47%) | ||
RA patients on leflunamide (%) | 53 (53%) | ||
RA patients on MTX and leflunamide compination (%) | 37 (37%) | ||
Current use of steroids (%) | 74 (74%) | ||
Cumulative steroid dose | 20.57 ± 5.057 | ||
Serum calcium (mean ± SD) | 8.32 ± 0.56 | 8.167 ± .299 | 0.3101 |
Serum phosphorus (mean ± SD) | 3.63 ± .815 | 3.325 ± 0.351 | 0.0021 |
RF positivity (%) | 68 (68%) | ||
HAQ-DI (mean ± SD) | 0.80 ± 0.497 | 0.176 ± 0.185 | < 0.00011 |
DAS28-ESR (mean ± SD) | 4.9 ± 1.4 | ||
DAS28-CRP (mean ± SD) | 4.1 ± 1.4 | ||
Low disease activity (%) | 18 (18%) | ||
Moderate disease activity (%) | 45 (45%) | ||
High disease activity (%) | 37 (37%) | ||
Previous fragility fractures (%) | 34 (34%) | 8 (15.68%) | 0.0332 |
Parental hip fractures (%) | 20 (20%) | 5 (9.8%) | 0.152 |
BMD at femoral neck in gm/cm2 | 0.918 ± 0.171 | 1.161 ± 0.262 | < 0.00011 |
BMD at lumbar spine in gm/cm2 | 1.03096 ± 0.221 | 1.197 ± 0.306 | 0.0041 |
BMD at total femur in gm/cm2 | 0.92038 ± 0.185 | 1.180 ± 0.331 | < 0.00011 |
Osteoporosis of lumbar spine (%) | 32 (32%) | 3 (5.88%) | 0.0012 |
Osteoporosis of femur (%) | 16 (16%) | 5 (9.8%) | |
Osteoporosis of both lumbar spine and femur (%) | 5 (5%) | 3 (5.88%) | |
FRAX of hip (mean ± SD) | 1.7640 ± 2.98942 | 0.380 ± 0.812 | < 0.00011 |
FRAX of major fractures (mean ± SD) | 5.304 ± 5.63921 | 2.168 ± 2.401 | < 0.00011 |
FRAX of hip ≥ 3 (%) | 16 (16%) | 2 (3.9%) | 0.0422 |
FRAX of major fractures ≥ 20 (%) | 12 (12%) | 0 (0%) | 0.0112 |
FRAX of major fractures ≥ 20 in postmenopausal women only (%) | 10 (22.7%) | 0 | 0.0482 |
FRAX of hip ≥ 3 in postmenopausal women only (%) | 14 (31.81%) | 2 (9.09%) | 0.0662 |